Immunotherapy proven to slow T1D progression in people newly diagnosed now being tested for prevention
Amber Van Den Heuvel received low-dose anti-thymocyte globulin (ATG) in 2015 as a participant in a TrialNet clinical study for people newly diagnosed with type 1 diabetes (T1D). Five years later, she still had beta cell function. Today, at age 26, Amber is encouraging people at high risk for T1D to consider participating in a TrialNet prevention study using the same therapy.
Newly diagnosed with type 1 diabetes? Help us find out if a novel combination therapy can preserve insulin production
TrialNet’s latest clinical study will test two established immune therapies—rituximab-pvvr followed by abatacept—to see if the combination can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D).
New onset study now open for enrollment — TrialNet launches study to test JAK inhibitors in type 1 diabetes
TrialNet researchers are testing two promising new treatments to see if either or both can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D).